Search International and National Patent Collections

1. (WO2017016523) ANTITUMOR COMPOUND TARGETING IDH2 MUTATION AND METHOD OF USE THEREOF

Pub. No.:    WO/2017/016523    International Application No.:    PCT/CN2016/092375
Publication Date: Fri Feb 03 00:59:59 CET 2017 International Filing Date: Sat Jul 30 01:59:59 CEST 2016
IPC: C07D 333/24
C07D 409/12
C07D 213/56
C07C 275/42
C07D 231/12
C07D 409/10
C07D 333/20
A61P 35/00
A61P 35/02
Applicants: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
正大天晴药业集团股份有限公司
LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD.
连云港润众制药有限公司
CENTAURUS BIOPHARMA CO., LTD.
北京赛林泰医药技术有限公司
Inventors: WANG, Shulong
王树龙
ZHAO, Na
赵娜
LIU, Xijie
刘希杰
HU, Yuandong
胡远东
ZHANG, Hui
张慧
LUO, Hong
罗鸿
PENG, Yong
彭勇
XIAO, Dengming
校登明
HAN, Yongxin
韩永信
ZHANG, Xiquan
张喜全
TIAN, Xin
田心
Title: ANTITUMOR COMPOUND TARGETING IDH2 MUTATION AND METHOD OF USE THEREOF
Abstract:
The present application relates to compounds represented by general formula (I), general formula (II) or general formula (III), and pharmaceutically acceptable salts or hydrates thereof, preparation methods thereof, and pharmaceutical compositions thereof. The compounds represented by general formula (I), general formula (II) or general formula (III) have inhibitory activities against isocitrate dehydrogenase 2 (IDH2), thereby being capable of treating IDH2 mutation-induced cancers.